RAF1 and non-small cell lung carcinoma: We observe similar responses in SW620 (CRC; Figure 2C, Supplementary Figure S3B, available at https://doi.org/10.1016/j.annonc.2020.10.483), A549 (Figure 2D), MIA-PaCa2 (Supplementary Figure S3C and D, available at https://doi.org/10.1016/j.annonc.2020.10.483) and Calu-1 cells (NSCLC, Supplementary Figure S3E, available at https://doi.org/10.1016/j.annonc.2020.10.483), where CCT3833 inhibits growth more effectively than all other RAF inhibitors, with only trametinib being significantly more potent.